Amplitude for A/L = 0.03. by Muhammad Hammad Bucha (21736111)

Subjects:

Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)

Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR. by Jordan A. Gunning (18143970)

Subjects:

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

S5 Fig - by Jordan K. Abbott (8934239)

Loss of <i>SLC4A11</i> expression in hCEnC leads to decreased cell barrier function. by Doug D. Chung (3611387)

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Equilibrium points and their corresponding eigenvalues of Eq (5). by Xinghua Fan (7344632)

The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

Decreases in locomotor responses to a single METH injection in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: